Search by conditions:


Protocol Description Phase
14-219 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16 years or greater  (View details on Phase II
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on Phase II
2 clinical trials listed

Back to Top